Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.5 HKD | +0.83% | +10.11% | -18.56% |
04-26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
Evolution of the average Target Price on RemeGen Co., Ltd.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering RemeGen Co., Ltd.
UBS |
EPS Revisions
- Stock Market
- Equities
- 9995 Stock
- Consensus RemeGen Co., Ltd.